Maze Therapeutics, Inc.
MAZE
$13.71
$0.403.01%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 6.97% | 4.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.03% | 19.09% | |||
| Operating Income | -3.03% | -19.09% | |||
| Income Before Tax | -2.72% | -9.82% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.72% | -10.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.72% | -10.84% | |||
| EBIT | -3.03% | -19.09% | |||
| EBITDA | -3.19% | -19.63% | |||
| EPS Basic | 32.85% | 43.24% | |||
| Normalized Basic EPS | 32.86% | 90.13% | |||
| EPS Diluted | 32.76% | 50.43% | |||
| Normalized Diluted EPS | 32.86% | 90.13% | |||
| Average Basic Shares Outstanding | 52.99% | 1,077.25% | |||
| Average Diluted Shares Outstanding | 52.99% | 1,077.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||